Guggenheim maintains GH Research at Buy, raises price target to $46 from $40

Guggenheim reaffirmed its Buy rating for GH Research and increased its price target to $46 from $40, citing a 151.8% potential upside from the Nov 17 close of $18.27. According to the firm, this represents a 15.0% increase in the target price.

Original reporting
Published Nov 18, 2026, 1:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Guggenheim maintains GH Research at Buy, raises price target to $46 from $40 — source image
Decision brief

The 30-second read

$GHBullishLow
01

Why it matters

The main tradable element is sentiment around the stock via a raised target, but the article lacks any new fundamental driver.

02

Market read

This is a single-name bullish analyst update that may influence short-term positioning, but it is unlikely to be a primary driver without accompanying company news.

03

What to watch

Traders may discount the target if other analysts are not moving, or if the implied upside is viewed as aggressive versus near-term catalysts.

Relevance 4/10Novelty 4/10Timing: today, as the analyst price-target update hits the tape

Background

The piece is an analyst note update, not an earnings, guidance, or corporate event report.

Company-level read

Ticker impact

$GHBullishMedium confidence
Context

Guggenheim maintained GH Research at Buy and raised its price target to $46 from $40, implying a large upside versus the Nov 17 close.

Expected impact

Likely modest upward bias as traders price in the higher target, with follow-through depending on broader analyst consensus.

Evidence & confidence

The article provides only an analyst rating and price-target change, with no new company-specific operational or financial datapoint.

Market effects

Minimal, since this is a single-name analyst target change with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A higher price target may reflect model assumptions rather than new information, so the stock may not move much if fundamentals have not changed.

Key entities

  • GH Research

    Subject of the analyst action: Buy rating maintained and price target raised to $46 from $40.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.